Patents by Inventor Xiangping Qian

Xiangping Qian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Certain chemical entities, compositions, and methods
    Patent number: 10912784
    Abstract: Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: February 9, 2021
    Assignee: SUZHOU NEUPHARMA CO., LTD.
    Inventor: Xiangping Qian
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20210032209
    Abstract: Chemical entities that are kinase inhibitors, their polymorphs, pharmaceutical compositions and methods of treatment of cancer are described herein.
    Type: Application
    Filed: February 7, 2019
    Publication date: February 4, 2021
    Inventor: Xiangping QIAN
  • BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER
    Publication number: 20200390763
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of using these chemical entities, e.g., for treatment of cancer are described.
    Type: Application
    Filed: August 26, 2020
    Publication date: December 17, 2020
    Inventors: Yong-Liang Zhu, Xiangping Qian
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20200354398
    Abstract: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: July 27, 2020
    Publication date: November 12, 2020
    Inventor: Xiangping QIAN
  • METHODS OF TREATING CANCER
    Publication number: 20200330486
    Abstract: The present invention relates to methods of treating cancer comprising administering a bufalin derivative compound of Formula I, wherein the compound is administered at least once a week for at least two weeks.
    Type: Application
    Filed: December 14, 2018
    Publication date: October 22, 2020
    Inventor: Xiangping QIAN
  • SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY
    Publication number: 20200306259
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: April 8, 2020
    Publication date: October 1, 2020
    Inventors: Xiangping QIAN, Yong-Liang ZHU
  • Certain chemical entities, compositions, and methods
    Patent number: 10766920
    Abstract: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: September 8, 2020
    Assignee: NEUPHARMA, INC.
    Inventor: Xiangping Qian
  • Amino-pyrimidine skeletal muscle modulators
    Patent number: 10765624
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: September 8, 2020
    Assignee: CYTOKINETICS, INC.
    Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu
  • Certain chemical entities, compositions, and methods
    Patent number: 10759766
    Abstract: Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically, quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: September 1, 2020
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Beautyberry total glycosides extract and preparation method and use thereof
    Patent number: 10758585
    Abstract: Disclosed is a composition comprising an beautyberry total glycosides extract, and a method of preparation thereof, and the use of the composition thereof in preparing drugs for treating neurodegenerative diseases or skin diseases. The extract thereof is prepared from the leaves of Callicarpa cathayana H.T. Chang or Callicarpa formosana Rolfe, and contains 18% to 45% verbascoside and 15% to 40% Arenarioside.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: September 1, 2020
    Assignee: Suzhou Neupharma Co., Ltd.
    Inventors: Jingge Liu, Yijun Cheng, Jinguo Cao, Yongliang Zhu, Xiangping Qian
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20200172495
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: December 4, 2019
    Publication date: June 4, 2020
    Inventors: Xiangping QIAN, Yong-Liang ZHU
  • Substituted quinazolines for inhibiting kinase activity
    Patent number: 10653701
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: May 19, 2020
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20200102344
    Abstract: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: October 8, 2019
    Publication date: April 2, 2020
    Inventor: Xiangping QIAN
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20200085846
    Abstract: Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: September 26, 2019
    Publication date: March 19, 2020
    Inventor: Xiangping Qian
  • Certain chemical entities, compositions, and methods
    Patent number: 10590106
    Abstract: Chemical entities that are quinoxaline kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: March 17, 2020
    Assignee: NeuPharma, Inc.
    Inventors: Yong-Liang Zhu, Xiangping Qian
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20200055828
    Abstract: Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically, quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described.
    Type: Application
    Filed: March 20, 2019
    Publication date: February 20, 2020
    Inventors: Xiangping QIAN, Yong-Liang ZHU
  • Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer
    Patent number: 10561652
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of using these chemical entities, e.g., for treatment of cancer are described.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: February 18, 2020
    Assignee: NEUPHARMA, INC.
    Inventors: Yong-Liang Zhu, Xiangping Qian
  • Certain chemical entities, compositions, and methods
    Patent number: 10544106
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: January 28, 2020
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20200024303
    Abstract: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: May 30, 2019
    Publication date: January 23, 2020
    Inventor: Xiangping QIAN
  • BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER
    Publication number: 20190365747
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of using these chemical entities, e.g., for treatment of cancer are described.
    Type: Application
    Filed: April 4, 2019
    Publication date: December 5, 2019
    Inventors: Yong-Liang Zhu, Xiangping Qian